Equities analysts forecast that Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) will announce sales of $5.18 million for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Dicerna Pharmaceuticals’ earnings, with estimates ranging from $350,000.00 to $10.00 million. Dicerna Pharmaceuticals posted sales of $130,000.00 in the same quarter last year, which would indicate a positive year over year growth rate of 3,884.6%. The company is expected to report its next earnings results on Thursday, March 29th.

On average, analysts expect that Dicerna Pharmaceuticals will report full year sales of $5.18 million for the current financial year, with estimates ranging from $500,000.00 to $10.90 million. For the next year, analysts expect that the firm will post sales of $7.25 million per share, with estimates ranging from $4.50 million to $10.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.70) by ($0.22). The firm had revenue of $0.47 million for the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. Dicerna Pharmaceuticals’s revenue was up 192.6% compared to the same quarter last year. During the same period last year, the company posted ($0.68) EPS.

Several brokerages have recently issued reports on DRNA. Zacks Investment Research lowered Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, November 2nd. HC Wainwright reiterated a “buy” rating and set a $10.00 price target (up from $6.00) on shares of Dicerna Pharmaceuticals in a report on Friday, November 3rd. Finally, Chardan Capital reiterated a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $6.81.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Northern Trust Corp lifted its holdings in Dicerna Pharmaceuticals by 6.1% in the 2nd quarter. Northern Trust Corp now owns 36,219 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 2,094 shares during the last quarter. Bourgeon Capital Management LLC lifted its holdings in Dicerna Pharmaceuticals by 188.9% in the 2nd quarter. Bourgeon Capital Management LLC now owns 39,000 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 25,500 shares during the last quarter. Birchview Capital LP lifted its holdings in Dicerna Pharmaceuticals by 125.0% in the 3rd quarter. Birchview Capital LP now owns 45,000 shares of the biopharmaceutical company’s stock worth $259,000 after purchasing an additional 25,000 shares during the last quarter. Deschutes Portfolio Strategy LLC acquired a new stake in Dicerna Pharmaceuticals in the 3rd quarter worth approximately $575,000. Finally, Vanguard Group Inc. lifted its holdings in Dicerna Pharmaceuticals by 4.5% in the 2nd quarter. Vanguard Group Inc. now owns 340,327 shares of the biopharmaceutical company’s stock worth $1,078,000 after purchasing an additional 14,517 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Shares of Dicerna Pharmaceuticals (DRNA) opened at $8.54 on Friday. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $10.24.

TRADEMARK VIOLATION WARNING: “Brokerages Anticipate Dicerna Pharmaceuticals, Inc. (DRNA) Will Announce Quarterly Sales of $5.18 Million” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.dailypolitical.com/2017/12/01/brokerages-anticipate-dicerna-pharmaceuticals-inc-drna-will-announce-quarterly-sales-of-5-18-million.html.

Dicerna Pharmaceuticals Company Profile

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get a free copy of the Zacks research report on Dicerna Pharmaceuticals (DRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.